Dr. De Carvalho and Dr. Bratman were recognized for 'their work on advancing a specialized form of circulating tumour DNA (ctDNA) technology, known as cfMeDIP-seq. cfMeDIP-seq is an ultra-sensitive cell-free DNA methylation pattern detection technology being developed to spot different types of cancers via liquid biopsy.'
Based on this research, Drs. De Carvalho and Bratman recently co-founded the start-up Adelato help improve the lives of patients. Adela is currently developing its biotech platform so that it can identify multiple types of cancers and other conditions with a simple blood test, rather than through traditional surgical biopsy.
Please join the Department of Medical Biophysics in congratulating Drs. De Carvalho and Dr. Bratman on this outstanding achievement.
